Archive for the ‘PBP Blog’ Category

Lobular Neoplasia Talk Now Posted

I recently gave a talk in Mexico City on lobular neoplasia (alh/lcis) which is now available here as a pdf: Lobular_neoplasia The talk covers the difference between ALH and LCIS and the new variants of LCIS such as pleomorphic LCIS and LCIS with necrosis. We also talk about the possibility that LCIS is a precursor [...]

Second Opinion Pathology Talk

I recently gave a talk on second opinions in breast pathology at the 21st Annual Conference of the National Consortium of Breast Centers in Las Vegas. A modified version of that talk is available here as a pdf: Second_Opinion_Pathology The first part of the talk covers some of the data in the literature and the [...]

Accelerated Partial Breast Irradiation and Ductal Carcinoma in Situ

In a recent issue of the journal Cancer there are two interesting articles looking at two types of radiation therapies vs. no radiation for a subset of patients with DCIS. This has long been a controversy amongst breast care specialists.  Does all DCIS following lumpectomy need to be treated by radiation? Or is there a [...]

Our Book Chapter on High Risk Lesions on Core Needle Biopsy

My radiology colleague from Harvard and I wrote a chapter on how women are being treated differently around the country and the world based on their core needle biopsy diagnosis. I posted the abstract a while back, but now we can publish the manuscript we wrote which is available here as a Word document: High [...]

Should Where You Live Determine Whether or Not You Need Surgery Following a Core Needle Biopsy?

Our book chapter on how women are treated disparately following a core needle breast biopsy of a “high risk” lesion has now been published in the current issue of Radiologic Clinics of North America. My colleague from Harvard Medical School and I want women to know that the current data in the breast cancer literature [...]

Prognostic Marker Changes in Metastatic Breast Cancer

There is a recent study published in the September 23 issue of Breast Cancer Research that looked at changes in prognostic markers (estrogen/progesterone receptor and HER2/neu) between primary breast cancers and metastatic lesions. If you click on the Breast Cancer Research link it will provide you with the abstract.  The full article is temporarily free from [...]

New York Times Article on Second Opinions in Breast Pathology

If you haven’t seen this recent article from the New York Times it’s worth a read. I have posted before about the importance of getting your breast biopsy diagnosed from a pathologist who specializes in breast pathology.  This article points out how subtle the distinction can be between atypical ductal hyperplasia and low grade ductal [...]

Update on My Post: Why is There No Consensus on How to Treat Some Diagnoses Found on Core Biopsy?

I wrote an article a while back called “What Your Core Needle Biopsy Diagnosis Means” to help patients understand why sometimes even a “benign” diagnosis may require a surgical excision.  While writing that article, I spoke to many of my colleagues in breast pathology and breast imaging and found out that there is a marked [...]

Interesting Consensus Conference Report on Core Needle Biopsy of the Breast

In the current issue of Cancer (April 1), there is a an interesting news article summarizing the findings of the 3rd International Consensus Conference on Image-Detected Breast Cancer. The expert panel suggests that in up to 35% of cases, patients are undergoing unnecessary open surgical biopsies as a first diagnostic procedure when core needle biopsy [...]

New Research on Using Immunohistochemistry to Predict Response to Neoadjuvant Chemotherapy

In the online “early view” section of the journal Cancer there is a new research article proposing that using three currently-used immunohistochemical breast markers in a group of patients who received neoadjuvant chemotherapy, doctors can sub-type cancers similar to those described by molecular profiling.  They also suggest these sub-types are associated with different responses to treatment and overall survival. [...]